Men's Health

In this article, Robert A. Dowling, MD, examines some of the practice-related implications of the rapid change in the management of patients with advanced prostate cancer.

Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.

This video demonstrates a subinguinal microscopic varicocelectomy without delivery of the testis.

Most health information seekers navigate the Internet for what they think will be the best information available about their health condition or that of a loved one. Unfortunately, the Internet is unfiltered, unregulated, and often saturated with promotional, unsubstantiated, and at times frightening information.

This video demonstrates a technique for single-port laparoscopic varicocelectomy using both transperitoneal and preperitoneal approaches.

Patients taking to the Internet for information about testosterone replacement therapy are likely getting an incomplete picture of the potential risks and adverse effects linked with the treatment, say researchers from Northwestern University Feinberg School of Medicine, Chicago, and the University of Pennsylvania, Philadelphia.

Panelists and audience members at the recent AUA “crossfire” debate on focal therapy show why the treatment is so controversial.

The cell surface amino acid glypican-1 (GPC-1) represents a potential new biomarker for prostate cancer, said Jonathan Henderson, MD, at the AUA annual meeting.

A novel metric for evaluating post-prostatectomy outcomes could support quality improvement initiatives for optimizing patient recovery.

Recently published research on a novel chemotherapy-immunotherapy combination is “exciting for multiple reasons,” says one expert.

A new study assesses how a biopsy-based gene test impacts prostate cancer treatment recommendations in three high-volume practices.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Post-radical prostatectomy radiation therapy in patients at risk of prostate cancer recurrence is on the wane in the U.S., despite evidence and guidelines supporting the practice, recently published research indicates.

A patient follow-up report shows promising mid-term results from five German urology centers that implemented the prostatic urethral lift (UroLift System, NeoTract, Inc.) to alleviate symptomatic BPH in patients suffering from mild, moderate, and even severe obstruction.

Biomarker models to predict disease progression in prostate cancer have a promising future, but at present, they have not fully justified their claimed clinical utilities, according to the authors of an independent review and analysis of the literature.

Laser photoselective vaporization prostatectomy using a 180W 532-nm lithium triborate laser (GreenLight XPS-180W laser system, American Medical Systems) is a safe and efficient option for treating BPH in men at high risk for surgical complications, according to findings from a large, international retrospective analysis.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

I am more optimistic that we will find a way to treat those who truly need to be treated and follow those unlikely to die from their disease.

In this article, James M. Hotaling, MD, MS, outlines the elements that comprise a cost-effective workup of the infertile male patient.

A newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.

Placement of a nerve “wrap” around the neurovascular bundle during nerve-sparing robot-assisted radical prostatectomy appears to accelerate the early restoration of continence and potency following surgery, a recently published study has shown.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.

The findings could help clinicians differentiate between slow-growing and aggressive tumors

The FDA has granted clearance to a hydrogel spacer for prostate cancer patients undergoing radiotherapy.

Final analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.

Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).

Men with prostate cancer who meet the criteria for active surveillance and undergo delayed radical prostatectomy after a period of active surveillance do not have a higher risk of adverse pathology compared with men with similar pre-treatment biopsy features who undergo immediate prostatectomy.

In men who take the 5-alpha-reductase inhibitor finasteride (Propecia) for hair loss, published data on its sexual side effects are insufficient to create a safety profile of the drug, according to a recent study.